Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Nabholtz JM, et al. Among authors: azli n. J Clin Oncol. 2003 Mar 15;21(6):968-75. doi: 10.1200/JCO.2003.04.040. J Clin Oncol. 2003. PMID: 12637459 Clinical Trial.
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N. Khayat D, et al. Among authors: azli n. J Clin Oncol. 2001 Jul 15;19(14):3367-75. doi: 10.1200/JCO.2001.19.14.3367. J Clin Oncol. 2001. PMID: 11454884 Clinical Trial.
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H. Fumoleau P, et al. Among authors: azli n. Ann Oncol. 1996 Feb;7(2):165-71. doi: 10.1093/oxfordjournals.annonc.a010544. Ann Oncol. 1996. PMID: 8777173 Free article. Clinical Trial.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: azli n. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Chevallier B, et al. Among authors: azli n. J Clin Oncol. 1995 Feb;13(2):314-22. doi: 10.1200/JCO.1995.13.2.314. J Clin Oncol. 1995. PMID: 7844592 Clinical Trial.
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N. Paridaens R, et al. Among authors: azli n. Ann Oncol. 2003 Mar;14(3):433-40. doi: 10.1093/annonc/mdg111. Ann Oncol. 2003. PMID: 12598350 Free article. Clinical Trial.
40 results